Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0B8WQ
|
|||
Former ID |
DIB020219
|
|||
Drug Name |
lisinopril-tryptophan
|
|||
Synonyms |
(S)-1-N2-(1-Carboxy-3-Phenylpropyl)-L-Lysyl-L-Tryptophan; Lisinopril-tryptophan; GTPL7893; N~2~-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-D-tryptophan; X95; (2S)-2-[[(2S)-6-amino-1-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-phenylbutanoic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C27H34N4O5
|
|||
Canonical SMILES |
C1=CC=C(C=C1)CCC(C(=O)O)NC(CCCCN)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)O
|
|||
InChI |
1S/C27H34N4O5/c28-15-7-6-12-22(30-23(26(33)34)14-13-18-8-2-1-3-9-18)25(32)31-24(27(35)36)16-19-17-29-21-11-5-4-10-20(19)21/h1-5,8-11,17,22-24,29-30H,6-7,12-16,28H2,(H,31,32)(H,33,34)(H,35,36)/t22-,23-,24+/m0/s1
|
|||
InChIKey |
JXNGDSIPMBNTNL-KMDXXIMOSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Inhibitor | [2] |
KEGG Pathway | Renin-angiotensin system | |||
Chagas disease (American trypanosomiasis) | ||||
Hypertrophic cardiomyopathy (HCM) | ||||
Pathwhiz Pathway | Angiotensin Metabolism | |||
Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
WikiPathways | ACE Inhibitor Pathway | |||
Metabolism of Angiotensinogen to Angiotensins |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7893). | |||
REF 2 | Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J. 2010 Apr 28;428(1):67-74. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.